Overview

A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature Infants

Status:
Active, not recruiting

Trial end date:
2025-02-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if an investigational drug can reduce the burden of chronic lung disease in extremely premature babies through 12 months corrected age (CA), as compared to extremely premature babies receiving standard neonatal care alone.

Phase:

Phase 2

Details

Lead Sponsor:

Shire

Treatments:

Mecasermin